<code id='2756480E3F'></code><style id='2756480E3F'></style>
      • <acronym id='2756480E3F'></acronym>
      <center id='2756480E3F'><center id='2756480E3F'><tfoot id='2756480E3F'></tfoot></center><abbr id='2756480E3F'><dir id='2756480E3F'><tfoot id='2756480E3F'></tfoot><noframes id='2756480E3F'>
      • <optgroup id='2756480E3F'><strike id='2756480E3F'><sup id='2756480E3F'></sup></strike><code id='2756480E3F'></code></optgroup>
        5. <b id='2756480E3F'><label id='2756480E3F'><select id='2756480E3F'><dt id='2756480E3F'><span id='2756480E3F'></span></dt></select></label></b><u id='2756480E3F'></u>
          <i id='2756480E3F'><strike id='2756480E3F'><tt id='2756480E3F'><pre id='2756480E3F'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-28 14:48:25 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：1
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Why the quest to eradicate polio has stumbled
                                
                            
          Next article：  
                                      
                                          Moonlake's readout produced a cash windfall. Risks remain
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles